Table 2. Vaccine and antiviral drug candidates evaluated using ferret models for SARS-CoV-2 prevention and treatment.

Category	Name	Features	Effect evaluation	Reference
Vaccines	Self-assembling RBD-nanoparticles	Protein-based vaccine	Antibodies	Kim et al., 2021b
	Ad5-nCoV	Adenoviral-vectored vaccine	Antibodies; T-cell responses	Wu et al., 2020
	ChAdOx1 nCoV-19	Adenoviral-vectored vaccine	Antibodies; T-cell responses	Lambe et al., 2021;Marsh et al., 2021
	SARS-CoV-2 antigens with L-pampo	Protein-based vaccine	Antibodies; T-cell responses	Jeong et al., 2021
	Covax-19TM	Protein-based vaccine	Antibodies	Li et al., 2021
	COVID-eVax	DNA vaccine	Antibodies; T-cell responses	Conforti et al., 2022;Compagnone et al., 2022
Antiviral drugs	Lopinavir/Ritonavir	Anti-HIV drugs, protease inhibitor	Clinical symptom (CS) values	Park et al., 2020
	Hydroxychloroquine sulfate	Autophagy inhibitor	Clinical symptom (CS) values	Park et al., 2020
	Emtricitabine/Tenofovir	Nucleotide analog that inhibits RNA-dependent RNA polymerase activity	Clinical symptom (CS) values; virus titers	Park et al., 2020
	Azathioprine	Immunosuppressive drug		Park et al., 2020
	Human placenta hydrolysate (hPH) (Laennec®)		Virus titers	Kim et al., 2021a
	Selinexor	XPO1 inhibitor	Viral load; inflammatory cytokine	Kashyap et al., 2021
	GS-621763	Oral prodrug of remdesivir parent nucleoside	Viral burden	Cox et al., 2021a
	EIDD-2749	Ribonucleoside analog	Viral burden; Viral titers	Sourimant et al., 2022
	CT-P59	Monoclonal antibody	Viral load	Ryu et al., 2021
	Molnupiravir	Orally bioavailable prodrug of ribonucleoside analog EIDD-1931	Viral shedding	Lieber et al., 2022
	OL-1 and OL-2	Probiotic consortia	Viral titers	Lehtinen et al., 2022